CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia
Alessandro Cafaro(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Claudio Cerchione(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Paolo Silimbani(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Carla Masini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Delia Cangini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giovanni Martinelli(University of Bologna), Maria Benedetta Giannini(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Andrea Ghelli Luserna di Rorà(Fondazione Pisa)
Cited by 13
Related Papers
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
|Blood|2011|460
Prospective, Randomized Study of Single Compared With Double Autologous Stem-Cell Transplantation for Multiple Myeloma: Bologna 96 Clinical Study
|Journal of Clinical Oncology|2007|374